Ma_Yi_Long的个人主页 - 老虎社区

Ma_Yi_Long

Ma_Yi_Long

暂无个人介绍

IP属地：未知

390关注

8粉丝

0主题

0勋章

2021-09-29

ok

抱歉，原内容已删除

2021-02-10

pls response to my comment here. thanks [开心]

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3557722898030015,"uuid":"3557722898030015","gmtCreate":1594629522194,"gmtModify":1615992096893,"name":"Ma_Yi_Long","pinyin":"mayilongmayilong","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/87e91b153216a6f84a5a4ac58894a42e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":390,"tweetSize":174,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.75%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.09","exceedPercentage":"93.21%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":862152979,"gmtCreate":1632847189874,"gmtModify":1632847189944,"author":{"id":"3557722898030015","authorId":"3557722898030015","name":"Ma_Yi_Long","avatar":"https://static.tigerbbs.com/87e91b153216a6f84a5a4ac58894a42e","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862152979","repostId":"2170724186","repostType":4,"isVote":1,"tweetType":1,"viewCount":572,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":381991118,"gmtCreate":1612918843234,"gmtModify":1703766902004,"author":{"id":"3557722898030015","authorId":"3557722898030015","name":"Ma_Yi_Long","avatar":"https://static.tigerbbs.com/87e91b153216a6f84a5a4ac58894a42e","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"pls response to my comment here. thanks [开心]&nbsp;","listText":"pls response to my comment here. thanks [开心]&nbsp;","text":"pls response to my comment here. thanks [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/381991118","repostId":"1176373590","repostType":4,"isVote":1,"tweetType":1,"viewCount":458,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":381991118,"gmtCreate":1612918843234,"gmtModify":1703766902004,"author":{"id":"3557722898030015","authorId":"3557722898030015","name":"Ma_Yi_Long","avatar":"https://static.tigerbbs.com/87e91b153216a6f84a5a4ac58894a42e","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"pls response to my comment here. thanks [开心]&nbsp;","listText":"pls response to my comment here. thanks [开心]&nbsp;","text":"pls response to my comment here. thanks [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/381991118","repostId":"1176373590","repostType":4,"repost":{"id":"1176373590","pubTimestamp":1612868893,"share":"https://www.laohu8.com/m/news/1176373590?lang=&edition=full","pubTime":"2021-02-09 19:08","market":"us","language":"en","title":"What new Amazon CEO Andy Jassy needs to do to become a leader in sustainability like Apple","url":"https://stock-news.laohu8.com/highlight/detail?id=1176373590","media":"MarketWatch","summary":"Andy Jassy, the incoming Amazon CEO, needs to improve labor relations, reduce packaging waste and fu","content":"<p>Andy Jassy, the incoming Amazon CEO, needs to improve labor relations, reduce packaging waste and further its climate goals if it wants to be a world-leading company from an environmental, social and governance perspective.</p>\n<p>Indeed, Amazon’s&nbsp;role model could be Apple,which advocates say has become a sustainability leader among megacap stocks.</p>\n<p>Amazon is starting to make strong operational strides such as investing in electric vehicles for its fleet and running data centers on renewable energy, but remains a laggard in other key ESG pillars such as workplace issues, racial and diversity inclusion and has more work to do on carbon reduction, say ESG advocates. Because of that, only a handle of ESG exchange-traded funds and mutual funds own the company.</p>\n<p>Outgoing CEO Jeff Bezos, the founder of the e-commerce giant, has “actually done the hard stuff, the hardest stuff being operations,” says Andrew Behar, CEO of As You Sow, a nonprofit shareholder advocacy group. “On other issues, though, he’s completely not even thinking about them.”</p>\n<p>Bezos will retain an influential position in the company as executive chairman and one of its largest shareholders. Jassy, the new CEO, is now the head of Amazon Web Services, the company’s cloud-computing business.</p>\n<p>Inhis letter to Amazon’s workforce, Bezos tried to burnish his ESG credentials:</p>\n<p>“As Amazon became large, we decided to use our scale and scope to lead on important social issues. Two high-impact examples: our $15 minimum wage and theClimate Pledge. In both cases, we staked out leadership positions and then asked others to come along with us. In both cases, it’s working. Other large companies are coming our way. I hope you’re proud of that as well.”</p>\n<p>Natasha Lamb, managing partner at Arjuna Capital, a sustainable and impact investment firm focusing on workplace issues for women and people of color, disputes Bezos’ claim of being a leader in these two areas, saying that there was great pressure on the company to increase worker pay and to sign the climate pledge.</p>\n<p>“He is not the poster child of the American dream, but of what is eating America alive, which is growing inequality,” she says.</p>\n<p>Amazonincreasedthe minimum wage to $15 in 2018 after years of criticism that it mistreated and underpaid workers, and the company caughtflakfor what workers said were poor health conditions in the pandemic. It is also fightinga unionization attempt at a warehouse in Alabama.</p>\n<p>Emanuele Colonnelli, an assistant professor of finance at the University of Chicago’s Booth School of Business who has done ESG research, agrees with Lamb. “A lot of the most promising steps toward ESG seem reactionary, as they have been taken only recently, at a moment in which regulatory and public pressure reached sky-high levels that became impossible to ignore,” he says.</p>\n<p>Although Amazon installed a higher minimum wage,MSCI&nbsp;considers the company a laggard when it comes to corporate behavior and labor management. Overall, MSCI gives Amazon a BBB rating, saying it is average for companies in the retail-consumer discretionary space.</p>\n<p>Lamb says Amazon has become what Walmartwas in the 1990s, criticized for shuttering small businesses. During the coronavirus, “everybody has become so reliant on Amazon, and those patterns are sticky. It has grave implications for small business.”</p>\n<p>Colonnelli says Amazon’s monopoly power can’t be denied and should be at the core of its ESG considerations. “It will be up to Jassy – and Bezos of course- to decide whether they want to be driving the change toward a business model that is less prone to anti-competitive practices, and therefore lead to a more equitable allocation of rents,” he says.</p>\n<p><b>A ‘real opportunity’ to be a leader</b></p>\n<p>Behar says As You Sow has interviewed Amazon employees and says the company has a “real opportunity” to be a leader on human capital management, such as increasing hourly employee wages, improving health care benefits, especially during the pandemic, and paid leave, as well as improving efforts around diversity equity inclusion.</p>\n<p>Lamb says with a new CEO coming on board, she wants greater clarity about defining gender and racial pay equity and to address diversity as a whole, noting that there are very few women and people of color in the company’s upper ranks. She says other shareholders are asking for a racial equity audit and for a worker representative on the board of directors, “which I think would be helpful.”</p>\n<p><b>Climate inroads</b></p>\n<p>When it comes to its climate pledge, Amazon is making some inroads. BloombergNEF said Amazon was the leading corporate buyer of clean energy in 2020, signing 35 separate clean energy power-purchasing agreements, totaling 5.1 gigawatts of power. BNEF says Amazon has now purchased over 7.5GW of clean energy to date, pushing it ahead of Alphabet GOOGL at 6.6GW and Facebook FB at 5.9GW as the world’s largest clean-energy buyer.</p>\n<p><img src=\"https://static.tigerbbs.com/f08942b5eaf8d39eb7fe60ce0ba75c91\" tg-width=\"620\" tg-height=\"432\" referrerpolicy=\"no-referrer\"></p>\n<p>Garvin Jabush, chief investment officer at Green Alpha Advisors, says Amazon’s investments in renewable energy and its $440 million&nbsp;investment&nbsp;in electric-truck start up Rivian are all impressive starts, but the company has a long way to go.</p>\n<p>Green Alpha Advisors doesn’t own Amazon because Jabush says it is still a large contributor to climate risk; he noted the company saw a 15% increase in carbon dioxide&nbsp;emissions&nbsp;in 2019. It also supplies advanced computing data to the oil and gas industry to help fossil-fuel companies locate new deposits.</p>\n<p>Both Jabush and Behar says Amazon faces material risk as it deals with electronic waste and plastic waste. Behar says it is trying to work with the e-commerce giant to reduce waste, noting the company could emulate Best Buy’s&nbsp;take-back program to recycle electronic waste. This could become a sustainable money maker by recouping the copper, gold and silver in used electronic parts, he says.</p>\n<p>Reducing plastic waste is also critical since Amazon is a big user of packaging. Amazon has reduced Styrofoam usage, but “they could commit to zero plastic in two to three years from now and it would make a big difference,” he says.</p>\n<p>Jabush says it’s always a debate at his firm each year about whether to buy Amazon because it is “a phenomenal business,” but he says until it reduces its climate impact, he won’t buy it. But with a new CEO, there’s an opportunity for change, Jabush says, pointing to how Tim Cook changed Apple after taking over from Steve Jobs.</p>\n<p>“Sustainability was low on their priority list, and Tim Cook has made Apple into by far the most sustainable megacap in the world right now,” he says.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What new Amazon CEO Andy Jassy needs to do to become a leader in sustainability like Apple</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat new Amazon CEO Andy Jassy needs to do to become a leader in sustainability like Apple\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-09 19:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/what-new-amazon-ceo-andy-jassy-needs-to-do-to-become-a-leader-in-sustainability-like-apple-11612444339?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Andy Jassy, the incoming Amazon CEO, needs to improve labor relations, reduce packaging waste and further its climate goals if it wants to be a world-leading company from an environmental, social and ...</p>\n\n<a href=\"https://www.marketwatch.com/story/what-new-amazon-ceo-andy-jassy-needs-to-do-to-become-a-leader-in-sustainability-like-apple-11612444339?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","AMZN":"亚马逊"},"source_url":"https://www.marketwatch.com/story/what-new-amazon-ceo-andy-jassy-needs-to-do-to-become-a-leader-in-sustainability-like-apple-11612444339?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1176373590","content_text":"Andy Jassy, the incoming Amazon CEO, needs to improve labor relations, reduce packaging waste and further its climate goals if it wants to be a world-leading company from an environmental, social and governance perspective.\nIndeed, Amazon’s role model could be Apple,which advocates say has become a sustainability leader among megacap stocks.\nAmazon is starting to make strong operational strides such as investing in electric vehicles for its fleet and running data centers on renewable energy, but remains a laggard in other key ESG pillars such as workplace issues, racial and diversity inclusion and has more work to do on carbon reduction, say ESG advocates. Because of that, only a handle of ESG exchange-traded funds and mutual funds own the company.\nOutgoing CEO Jeff Bezos, the founder of the e-commerce giant, has “actually done the hard stuff, the hardest stuff being operations,” says Andrew Behar, CEO of As You Sow, a nonprofit shareholder advocacy group. “On other issues, though, he’s completely not even thinking about them.”\nBezos will retain an influential position in the company as executive chairman and one of its largest shareholders. Jassy, the new CEO, is now the head of Amazon Web Services, the company’s cloud-computing business.\nInhis letter to Amazon’s workforce, Bezos tried to burnish his ESG credentials:\n“As Amazon became large, we decided to use our scale and scope to lead on important social issues. Two high-impact examples: our $15 minimum wage and theClimate Pledge. In both cases, we staked out leadership positions and then asked others to come along with us. In both cases, it’s working. Other large companies are coming our way. I hope you’re proud of that as well.”\nNatasha Lamb, managing partner at Arjuna Capital, a sustainable and impact investment firm focusing on workplace issues for women and people of color, disputes Bezos’ claim of being a leader in these two areas, saying that there was great pressure on the company to increase worker pay and to sign the climate pledge.\n“He is not the poster child of the American dream, but of what is eating America alive, which is growing inequality,” she says.\nAmazonincreasedthe minimum wage to $15 in 2018 after years of criticism that it mistreated and underpaid workers, and the company caughtflakfor what workers said were poor health conditions in the pandemic. It is also fightinga unionization attempt at a warehouse in Alabama.\nEmanuele Colonnelli, an assistant professor of finance at the University of Chicago’s Booth School of Business who has done ESG research, agrees with Lamb. “A lot of the most promising steps toward ESG seem reactionary, as they have been taken only recently, at a moment in which regulatory and public pressure reached sky-high levels that became impossible to ignore,” he says.\nAlthough Amazon installed a higher minimum wage,MSCI considers the company a laggard when it comes to corporate behavior and labor management. Overall, MSCI gives Amazon a BBB rating, saying it is average for companies in the retail-consumer discretionary space.\nLamb says Amazon has become what Walmartwas in the 1990s, criticized for shuttering small businesses. During the coronavirus, “everybody has become so reliant on Amazon, and those patterns are sticky. It has grave implications for small business.”\nColonnelli says Amazon’s monopoly power can’t be denied and should be at the core of its ESG considerations. “It will be up to Jassy – and Bezos of course- to decide whether they want to be driving the change toward a business model that is less prone to anti-competitive practices, and therefore lead to a more equitable allocation of rents,” he says.\nA ‘real opportunity’ to be a leader\nBehar says As You Sow has interviewed Amazon employees and says the company has a “real opportunity” to be a leader on human capital management, such as increasing hourly employee wages, improving health care benefits, especially during the pandemic, and paid leave, as well as improving efforts around diversity equity inclusion.\nLamb says with a new CEO coming on board, she wants greater clarity about defining gender and racial pay equity and to address diversity as a whole, noting that there are very few women and people of color in the company’s upper ranks. She says other shareholders are asking for a racial equity audit and for a worker representative on the board of directors, “which I think would be helpful.”\nClimate inroads\nWhen it comes to its climate pledge, Amazon is making some inroads. BloombergNEF said Amazon was the leading corporate buyer of clean energy in 2020, signing 35 separate clean energy power-purchasing agreements, totaling 5.1 gigawatts of power. BNEF says Amazon has now purchased over 7.5GW of clean energy to date, pushing it ahead of Alphabet GOOGL at 6.6GW and Facebook FB at 5.9GW as the world’s largest clean-energy buyer.\n\nGarvin Jabush, chief investment officer at Green Alpha Advisors, says Amazon’s investments in renewable energy and its $440 million investment in electric-truck start up Rivian are all impressive starts, but the company has a long way to go.\nGreen Alpha Advisors doesn’t own Amazon because Jabush says it is still a large contributor to climate risk; he noted the company saw a 15% increase in carbon dioxide emissions in 2019. It also supplies advanced computing data to the oil and gas industry to help fossil-fuel companies locate new deposits.\nBoth Jabush and Behar says Amazon faces material risk as it deals with electronic waste and plastic waste. Behar says it is trying to work with the e-commerce giant to reduce waste, noting the company could emulate Best Buy’s take-back program to recycle electronic waste. This could become a sustainable money maker by recouping the copper, gold and silver in used electronic parts, he says.\nReducing plastic waste is also critical since Amazon is a big user of packaging. Amazon has reduced Styrofoam usage, but “they could commit to zero plastic in two to three years from now and it would make a big difference,” he says.\nJabush says it’s always a debate at his firm each year about whether to buy Amazon because it is “a phenomenal business,” but he says until it reduces its climate impact, he won’t buy it. But with a new CEO, there’s an opportunity for change, Jabush says, pointing to how Tim Cook changed Apple after taking over from Steve Jobs.\n“Sustainability was low on their priority list, and Tim Cook has made Apple into by far the most sustainable megacap in the world right now,” he says.","news_type":1},"isVote":1,"tweetType":1,"viewCount":458,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862152979,"gmtCreate":1632847189874,"gmtModify":1632847189944,"author":{"id":"3557722898030015","authorId":"3557722898030015","name":"Ma_Yi_Long","avatar":"https://static.tigerbbs.com/87e91b153216a6f84a5a4ac58894a42e","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862152979","repostId":"2170724186","repostType":4,"repost":{"id":"2170724186","pubTimestamp":1632843061,"share":"https://www.laohu8.com/m/news/2170724186?lang=&edition=full","pubTime":"2021-09-28 23:31","market":"us","language":"en","title":"3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2170724186","media":"Motley Fool","summary":"Analysts expect one of them could skyrocket more than 40% over the next 12 months.","content":"<p>Many investors like to buy shares of large drugmakers for the relative stability that they provide. But tremendous growth often isn't expected from these stocks.</p>\n<p>That doesn't mean, though, that strong growth is always out of the question for top biopharmaceutical companies.&nbsp;Here are three big pharma stocks that Wall Street thinks could soar by at least 30% within the next 12 months.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F644349%2Fanalysts-looking-at-stock-charts.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bristol Myers Squibb</h2>\n<p>The consensus Wall Street price target for&nbsp;<b>Bristol Myers Squibb</b> (NYSE:BMY) reflects a premium of nearly 34% to the current share price. Of the 22 analysts surveyed by Refinitiv, the most pessimistic of the group thinks that the pharma stock could jump at least 10% higher.</p>\n<p>This bullishness might be somewhat surprising. BMS' top-selling product, Revlimid, faces generic competition beginning next year. The blood cancer drug generated 27% of the company's total revenue in the second quarter.</p>\n<p>So why do analysts like BMS so much? For <a href=\"https://laohu8.com/S/AONE.U\">one</a> thing, that generic competition will only be in limited volumes at first thanks to contractual agreements. The company also has several other blockbusters with strong sales growth, notably including blood thinner Eliquis and cancer immunotherapies Opdivo and Yervoy.</p>\n<p>BMS' lineup is loaded with newer drugs with tremendous potential as well. Cancer cell therapies Abecma and Breyanzi along with multiple sclerosis and ulcerative colitis drug Zeposia especially stand out. Over the next few years, these and other drugs could help make up for anticipated sales declines for Revlimid.</p>\n<h2>2. <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a></h2>\n<p>Analysts look for an even better performance over the next 12 months from&nbsp;<b>Sanofi</b> (NASDAQ:SNY). The average price target for the French drugmaker is 35% above the current share price. The lowest target for Sanofi among the three analysts surveyed by Refinitiv expects the pharma stock to soar by at least 20%.</p>\n<p>Sanofi's partnership with <b>Regeneron</b>&nbsp;gives the company multiple growth drivers. Sales of Dupixent are skyrocketing and could pick up more momentum with the U.S. Food and Drug Administration's new restrictions on JAK inhibitors. Cancer drug Libtayo continues to gain steam with additional approved indications.</p>\n<p>Regeneron isn't helping Sanofi on every front, though. The big drugmaker has several products of its own with strong sales growth, including rare blood disorder drug Cablivi, type 2 diabetes drug Soliqua, and its vaccines franchise.</p>\n<p>Investors also get an added bonus with Sanofi -- its dividend. The company's dividend yield currently tops 4%, which makes Sanofi one of the most attractive pharma stocks for income-seeking investors.</p>\n<h2>3. Vertex Pharmaceuticals</h2>\n<p>Wall Street is especially enthusiastic about the prospects for&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX). The consensus price target for the stock is nearly 41% above the current share price. Twenty-two of the 27 analysts surveyed by Refinitiv view Vertex as a buy or strong buy with the other two analysts recommending holding the stock.</p>\n<p>The primary reason behind this bullishness is Vertex's cystic fibrosis (CF) franchise. There are only four approved CF drugs in the U.S. and Europe that treat the underlying cause of the genetic disease. Vertex markets all of them. The company's CF drugs should be able to generate even higher sales as Vertex picks up additional reimbursement deals and regulatory approvals.</p>\n<p>Vertex could have a non-CF drug on the market in the not-too-distant future. The company is partnering with <b>CRISPR Therapeutics</b>&nbsp;to develop gene-editing therapy CTX001 in treating rare blood disorders beta-thalassemia and sickle cell disease. Vertex and CRISPR Therapeutics hope to be able to file for regulatory approvals as soon as 2023.</p>\n<p>Other pipeline candidates could also provide catalysts for the stock. Vertex expects to report results from a phase 2 study evaluating VX-147 in treating APOL1-mediated focal segmental glomerulosclerosis (FSGS) later this year. Data from a phase 2 study of VX-548 in treating acute pain following bunionectomy surgery should be announced in early 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 23:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-big-pharma-stocks-wall-street-thinks-could-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Many investors like to buy shares of large drugmakers for the relative stability that they provide. But tremendous growth often isn't expected from these stocks.\nThat doesn't mean, though, that strong...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-big-pharma-stocks-wall-street-thinks-could-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","SNY":"赛诺菲安万特","BMY":"施贵宝"},"source_url":"https://www.fool.com/investing/2021/09/28/3-big-pharma-stocks-wall-street-thinks-could-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170724186","content_text":"Many investors like to buy shares of large drugmakers for the relative stability that they provide. But tremendous growth often isn't expected from these stocks.\nThat doesn't mean, though, that strong growth is always out of the question for top biopharmaceutical companies. Here are three big pharma stocks that Wall Street thinks could soar by at least 30% within the next 12 months.\nImage source: Getty Images.\n1. Bristol Myers Squibb\nThe consensus Wall Street price target for Bristol Myers Squibb (NYSE:BMY) reflects a premium of nearly 34% to the current share price. Of the 22 analysts surveyed by Refinitiv, the most pessimistic of the group thinks that the pharma stock could jump at least 10% higher.\nThis bullishness might be somewhat surprising. BMS' top-selling product, Revlimid, faces generic competition beginning next year. The blood cancer drug generated 27% of the company's total revenue in the second quarter.\nSo why do analysts like BMS so much? For one thing, that generic competition will only be in limited volumes at first thanks to contractual agreements. The company also has several other blockbusters with strong sales growth, notably including blood thinner Eliquis and cancer immunotherapies Opdivo and Yervoy.\nBMS' lineup is loaded with newer drugs with tremendous potential as well. Cancer cell therapies Abecma and Breyanzi along with multiple sclerosis and ulcerative colitis drug Zeposia especially stand out. Over the next few years, these and other drugs could help make up for anticipated sales declines for Revlimid.\n2. Sanofi\nAnalysts look for an even better performance over the next 12 months from Sanofi (NASDAQ:SNY). The average price target for the French drugmaker is 35% above the current share price. The lowest target for Sanofi among the three analysts surveyed by Refinitiv expects the pharma stock to soar by at least 20%.\nSanofi's partnership with Regeneron gives the company multiple growth drivers. Sales of Dupixent are skyrocketing and could pick up more momentum with the U.S. Food and Drug Administration's new restrictions on JAK inhibitors. Cancer drug Libtayo continues to gain steam with additional approved indications.\nRegeneron isn't helping Sanofi on every front, though. The big drugmaker has several products of its own with strong sales growth, including rare blood disorder drug Cablivi, type 2 diabetes drug Soliqua, and its vaccines franchise.\nInvestors also get an added bonus with Sanofi -- its dividend. The company's dividend yield currently tops 4%, which makes Sanofi one of the most attractive pharma stocks for income-seeking investors.\n3. Vertex Pharmaceuticals\nWall Street is especially enthusiastic about the prospects for Vertex Pharmaceuticals (NASDAQ:VRTX). The consensus price target for the stock is nearly 41% above the current share price. Twenty-two of the 27 analysts surveyed by Refinitiv view Vertex as a buy or strong buy with the other two analysts recommending holding the stock.\nThe primary reason behind this bullishness is Vertex's cystic fibrosis (CF) franchise. There are only four approved CF drugs in the U.S. and Europe that treat the underlying cause of the genetic disease. Vertex markets all of them. The company's CF drugs should be able to generate even higher sales as Vertex picks up additional reimbursement deals and regulatory approvals.\nVertex could have a non-CF drug on the market in the not-too-distant future. The company is partnering with CRISPR Therapeutics to develop gene-editing therapy CTX001 in treating rare blood disorders beta-thalassemia and sickle cell disease. Vertex and CRISPR Therapeutics hope to be able to file for regulatory approvals as soon as 2023.\nOther pipeline candidates could also provide catalysts for the stock. Vertex expects to report results from a phase 2 study evaluating VX-147 in treating APOL1-mediated focal segmental glomerulosclerosis (FSGS) later this year. Data from a phase 2 study of VX-548 in treating acute pain following bunionectomy surgery should be announced in early 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":572,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}